UPDATE: Piper Jaffray Initiates OPKO Health With Overweight, $2.50 Target Notes 'Partner Pfizer recently reported positive Phase III data on once-weekly somatrogon in pediatric Growth Hormone Deficiency'; Pfizer Anticipates Filing 'BLA 2H:20'